109 0 Kommentare Advanced Therapy Medicinal Products CDMO Market is expected to display a steady growth of 14% due to the rise in research & development activities | UnivDatos Market Insights - Seite 2

Some of the major players operating in the market include CELONIC Group; FUJIFILM Corporation; Bio Elpida; Rentschler Biopharma SE; AGC Biologics; Catalent, Inc; Lonza; WuXi AppTec Co., Ltd.; BlueReg; Thermo Fisher Scientific Inc.

COVID-19 Impact

The COVID-19 pandemic has had a significant impact on the advanced therapy medicinal products CDMO market. The pandemic led to disruptions in supply chains, and slowdown in production and distribution activities. Additionally, the pandemic also resulted in a decrease in investment and funding for research and development in the ATMPs sector, which has affected the growth of the ATMPs CDMO market.

The global advanced therapy medicinal products CDMO market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

Based on product, the market is segmented into gene therapy, cell therapy, tissue engineered, and others. Amongst, cell therapy category to witness fastest growth rate during the forecast period. This segment includes the production and manufacturing of cellular products, such as stem cells, T-cells, and other cell-based treatments, which are used to treat a range of diseases and conditions, including cancer, genetic disorders, and degenerative diseases. Companies in this segment offer a range of services, including cell processing, cell banking, and cell therapy product development and commercialization. These factors are expected to contribute to the growth of this segment.
On the basis of indication, the market is categorized into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, and others. Among these, the cardiology category held a significant share in the market in 2020. This is mainly due to the several factors, including the increasing prevalence of cardiovascular diseases such as heart attack, stroke, and heart failure, which are leading causes of death and disability worldwide. The increasing prevalence of these diseases is driving the demand for new and innovative treatments, including ATMPs.